Jennifer Doudna’s New Gene Editing Company Launches With A $20 Million Round To Develop Genetic Medicines

Forbes
|
October 6, 2020
X min read
Forbes
|
October 6, 2020
Share on Social
share on Twitter or X
share on Linkedin
share onFacebook
share on Bluesky